Market Place
Sourcing Support
All News #Library
Biotech
EC Approves Crinetics` PALSONIFY for Acromegaly in Adults
26 Apr 2026 //
GLOBENEWSWIRE
Crinetics Pharma Submits Palsonify For Acromegaly In Brazil
26 Mar 2026 //
GLOBENEWSWIRE
Crinetics Starts Pediatric Phase 2/3 Trial For Atumelnant In CAH
22 Jan 2026 //
GLOBENEWSWIRE
Crinetics Unveils New Data, Funding as Neurocrine Rival
07 Jan 2026 //
BIOSPACE
Crinetics Reports Strong PALSONIFY Launch, Positive CAH Data
05 Jan 2026 //
GLOBENEWSWIRE
Crinetics Pharma Announces PALSONIFY & Atumelnant Update
04 Jan 2026 //
GLOBENEWSWIRE
Crinetics Announces First Patient Dosed in Adrenal Hyperplasia
11 Dec 2025 //
GLOBENEWSWIRE
Crinetics Initiates Phase 1/2 Trial For CRN09682
03 Dec 2025 //
GLOBENEWSWIRE
Sana, CAMP4 Ditch Clinical-Stage Assets for Preclinical Hopefuls
07 Nov 2025 //
FIERCE BIOTECH
Crinetics Pharma Reveals Q3 2025 Financials & Business Update
06 Nov 2025 //
GLOBENEWSWIRE
Crinetics to Present Neuroendocrine Tumor Data at NANETS 2025
23 Oct 2025 //
GLOBENEWSWIRE
FDA Approves Crinetics` Once-Daily Acromegaly Treatment
26 Sep 2025 //
BIOSPACE
Crinetics Pharmaceuticals Reports Q2 2025 Results, Updates
07 Aug 2025 //
GLOBENEWSWIRE
Crinetics to Present PALSONIFY Acromegaly Data at ENDO 2025
13 Jul 2025 //
GLOBENEWSWIRE
Crinetics to Showcase Endocrinology Innovation at ENDO 2025
30 Jun 2025 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.